CSIMarket Company Name, Ticker, Industry, else..


Entrada Therapeutics Inc   (NASDAQ: TRDA)
Other Ticker:  
 

Entrada Therapeutics Inc

TRDA's Fundamental analysis



Entrada Therapeutics Inc 's sales fell by -55.25 % in III. Quarter 2024 from the same quarter a year ago. Ranking at No. 140

Major Pharmaceutical Preparations industry recorded growth of revenues by 9.72 %

Entrada Therapeutics Inc 's net profit decreased by -96.52 % in III. Quarter 2024 year on year, to $2 millions.

• More on TRDA's Growth


Entrada Therapeutics Inc
current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.

Entrada Therapeutics Inc PEG ratio is at -0.03 Company is currently trading with Price to Cash flow multiple of 33.77 in trailing twelve-month period.
Company
13.51
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 4.11.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.28.


• More on TRDA's Valuation
 
 Total Debt (Millions $) -
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ 2,869,760
 Net Income/Employee (TTM) $ 1,769,973
 Receivable Turnover (TTM) -
 Tangible Book Value (Per Share $) 10.40

Entrada Therapeutics Inc
current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.

Entrada Therapeutics Inc PEG ratio is at -0.03 Company is currently trading with Price to Cash flow multiple of 33.77 in trailing twelve-month period.
Company
13.51
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 4.11.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.28.

Entrada Therapeutics Inc Price to Book Ratio is at 2.09 lower than Industry Avg. of 81.16. and higher than S&P 500 Avg. of 0.01

• More on TRDA's Valuation

•  Market Capitalization (Millions $) 884
•  Shares Outstanding (Millions) 41
•  Employees 75
•  Revenues (TTM) (Millions $) 215
•  Net Income (TTM) (Millions $) 133
•  Cash Flow (TTM) (Millions $) 26
•  Capital Exp. (TTM) (Millions $) -4
•  Total Debt (Millions $) -
•  Dividend TTM ($) 0 $
•  Dividend Yield TTM (%) -
•  Revenue/Employee (TTM) $ 2,869,760
•  Net Income/Employee(TTM) $ 1,769,973
•  Receivable Turnover Ratio (TTM) -
•  Tangible Book Value (Per Share $) 10.40

•  Market Capitalization (Millions $) 884
•  Shares Outstanding (Millions) 41
•  Employees 75
•  Revenues (TTM) (Millions $) 215
•  Net Income (TTM) (Millions $) 133
•  Cash Flow (TTM) (Millions $) 26
•  Capital Exp. (TTM) (Millions $) -4





  Ratio
•   Capital Ratio (MRQ) 6.59
•  Total Debt to Equity (MRQ) -
•  Tangible Leverage Ratio (MRQ) 0.31
•  Asset Turnover Ratio (TTM) 0.48
•  Inventory Turnover Ratio (TTM) -





Entrada Therapeutics Inc net profit margin of 9.5 % is currently ranking no. 42 in Major Pharmaceutical Preparations industry, ranking no. 112 in Healthcare sector and number 1289 in S&P 500.

• More on TRDA's Key Ratios





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com